NCT02077192 2023-12-11Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)Rigel PharmaceuticalsPhase 3 Completed123 enrolled 11 charts 1 FDA